Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Pharma Mar

- PMLiVE

Sanofi gets cardio outcomes claim for Praluent in EU

Data stronger than rival's, could spark a fight back

- PMLiVE

CHMP recommends new Keytruda dosing schedule

Will apply to eight indications across five tumour types

- PMLiVE

GSK, J&J say monthly injection keeps HIV controlled

The once every four-week treatment could free those from taking daily pills

- PMLiVE

Amgen, Servier start second phase 3 trial of heart failure hope

Treatment is one of few in underserved area

- PMLiVE

Evenity back on track with FDA panel blessing in osteoporosis

US drugs regulator first rejected the drug due to cardiovascular concerns

- PMLiVE

Novartis withdraws EU filing for canakinumab

Further setback for cardiovascular blockbuster potential

- PMLiVE

Amgen’s BCMA drug on course to challenge CAR-Ts in myeloma

BiTE will rival therapies from Bluebird, Celgene/Juno, J&J/Legend biotech

- PMLiVE

MSD claims EU approval for two HIV products

Company battles back against dominant Gilead and GSK

- PMLiVE

CHMP backs Sanofi’s all-oral sleeping sickness drug

Sanofi's drug and others given green light by EMA committee

- PMLiVE

Roche pulls EU Tecentriq/Avastin filing in kidney cancer

Another setback for Roche, but CHMP changes its mind on Opdivo/Yervoy

- PMLiVE

Amgen CEO says Aimovig is “one of most successful launches”

Contrasts with cholesterol drug Repatha, its price slahed 60% to lift take-up

- PMLiVE

GSK’s says depot HIV injection works over three years

The injection could rival Gilead’s single-tablet therapy

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links